Published in Cancer Weekly, March 16th, 2004
"F-18-FDG PET offers the radiation oncology community the ability to incorporate biologic information into radiation therapy targets. To date, most of the work in this arena has involved patients with non-small cell lung cancer (NSCLC)," researchers in the United States report.
"The literature suggests that biologic targeting with PET alters the radiation treatment volume significantly in 30%-60% of NSCLC patients for whom definitive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.